未找到相关数据
A phase I study of the tolerability, safety, pharmacokinetics and preliminary antitumor effects of KBP-5209, a novel pan-HER inhibitor, in patients with advanced solid tumors.
被引：0
作者：
Piha-Paul, Sarina Anne
Sharma, Sunil
Shih, Chengkon
O'Neil, Bert H.
Zhou, Qinghong
Ding, Yuli
Ou, Na
Yu, Tingting
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[3] XuanZhu Pharma, Jinan, Shandong, Peoples R China
[4] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[5] Sihuan Pharma, Beijing, Peoples R China
[6] XuanZhu Pharma, Jinan, Shandong, Peoples R China
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.2565
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2565
引用
收藏
页数：5
相关论文